HMGB1 and COVID-19: Plasma concentrations of HMGB1 are significantly elevated in critically ill COVID-19 patients, especially in those who do not survive (p < 0.001), and are associated with worse SOFA scores (>10), septic shock, and adverse outcomes such as acute kidney injury